Calcium signals and potential therapy targets in ovarian cancer (Review)

Deng,Fengying; Fu,Mengyu; Zhao,Chenxuan; Lei,Jiahui; Xu,Ting; Ji,Bingyu; Ding,Hongmei; Zhang,Yueming; Chen,Jie; Qiu,Junlan; Gao,Qinqin

doi:10.3892/ijo.2023.5573

Calcium signals and potential therapy targets in ovarian cancer (Review)

Authors:
- Fengying Deng
- Mengyu Fu
- Chenxuan Zhao
- Jiahui Lei
- Ting Xu
- Bingyu Ji
- Hongmei Ding
- Yueming Zhang
- Jie Chen
- Junlan Qiu
- Qinqin Gao
View Affiliations

Affiliations: Institute for Fetology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of Gynecology and Obstetrics, Dushu Lake Hospital Affiliated to Soochow University, Suzhou, Jiangsu 215100, P.R. China, Department of Oncology and Hematology, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, Jiangsu 215153, P.R. China
Published online on: September 12, 2023 https://doi.org/10.3892/ijo.2023.5573
Article Number: 125
Copyright: © Deng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer (OC) is a deadly disease. The poor prognosis and high lethality of OC are attributed to its high degrees of aggressiveness, resistance to chemotherapy and recurrence rates. Calcium ion (Ca²⁺) signaling has received attention in recent years, as it appears to form an essential part of various aspects of cancer pathophysiology and is a potential therapeutic target for OC treatment. Disruption of normal Ca²⁺ signaling pathways can induce changes in cell cycle progression, apoptosis, proliferation and migration and invasion, leading to the development of the malignant phenotype of tumors. In the present review, the main roles of ion channel/receptor/pump‑triggered Ca²⁺ signaling pathways located at the plasma membrane and organelle Ca²⁺ transport in OC are summarized. In addition, the potential of Ca²⁺ signaling as a novel target for the development of effective treatment strategies for OC was discussed. Furthering the understanding into the role of Ca²⁺ signaling in OC is expected to facilitated the identification of novel therapeutic targets and improved clinical outcomes for patients.

View Figures

View References

1	Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M and Allemani C; the CONCORD Working Group: The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecol Oncol. 144:405–413. 2017. View Article : Google Scholar
2	Lisio MA, Fu L, Goyeneche A, Gao ZH and Telleria C: High-grade serous ovarian cancer: Basic sciences, clinical and therapeutic standpoints. Int J Mol Sci. 20:9522019. View Article : Google Scholar : PubMed/NCBI
3	Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J and Karlan BY: Ovarian cancer. Nat Rev Dis Primers. 2:160612016. View Article : Google Scholar : PubMed/NCBI
4	Mallen A, Soong TR, Townsend MK, Wenham RM, Crum CP and Tworoger SS: Surgical prevention strategies in ovarian cancer. Gynecol Oncol. 151:166–175. 2018. View Article : Google Scholar : PubMed/NCBI
5	Menon U, Karpinskyj C and Gentry-Maharaj A: Ovarian cancer prevention and screening. Obstet Gynecol. 131:909–927. 2018. View Article : Google Scholar : PubMed/NCBI
6	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
7	Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL: Ovarian cancer statistics, 2018. CA Cancer J Clin. 68:284–296. 2018. View Article : Google Scholar : PubMed/NCBI
8	O'Malley DM: New therapies for ovarian cancer. J Natl Compr Canc Netw. 17:619–621. 2019.PubMed/NCBI
9	Zhang M, Cheng S, Jin Y, Zhao Y and Wang Y: Roles of CA125 in diagnosis, prediction and oncogenesis of ovarian cancer. Biochim Biophys Acta Rev Cancer. 1875:1885032021. View Article : Google Scholar
10	Berridge MJ, Lipp P and Bootman MD: The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol. 1:11–21. 2000. View Article : Google Scholar
11	Altamura C, Greco MR, Carratù MR, Cardone RA and Desaphy JF: Emerging roles for ion channels in ovarian cancer: Pathomechanisms and pharmacological treatment. Cancers (Basel). 13. pp. 6682021, View Article : Google Scholar
12	Caravia L, Staicu CE, Radu BM, Condrat CE, Crețoiu D, Bacalbașa N, Suciu N, Crețoiu SM and Voinea SC: Altered organelle calcium transport in ovarian physiology and cancer. Cancers (Basel). 12:22322020. View Article : Google Scholar : PubMed/NCBI
13	Monteith GR, McAndrew D, Faddy HM and Roberts-Thomson SJ: Calcium and cancer: Targeting Ca2+ transport. Nat Rev Cancer. 7:519–530. 2007. View Article : Google Scholar : PubMed/NCBI
14	McConkey DJ and Orrenius S: The role of calcium in the regulation of apoptosis. Biochem Biophys Res Commun. 239:357–366. 1997. View Article : Google Scholar : PubMed/NCBI
15	Prevarskaya N, Skryma R and Shuba Y: Calcium in tumour metastasis: New roles for known actors. Nat Rev Cancer. 11:609–618. 2011. View Article : Google Scholar : PubMed/NCBI
16	Pulliam TL, Goli P, Awad D, Lin C, Wilkenfeld SR and Frigo DE: Regulation and role of CAMKK2 in prostate cancer. Nat Rev Urol. 19:367–380. 2022. View Article : Google Scholar : PubMed/NCBI
17	Venkatachalam K, Luo J and Montell C: Evolutionarily conserved, multitasking TRP channels: Lessons from worms and flies. Handb Exp Pharmacol. 223:937–962. 2014. View Article : Google Scholar : PubMed/NCBI
18	Chen JP, Wang J, Luan Y, Wang CX, Li WH, Zhang JB, Sha D, Shen R, Cui YG, Zhang Z, et al: TRPM7 promotes the metastatic process in human nasopharyngeal carcinoma. Cancer Lett. 356:483–490. 2015. View Article : Google Scholar
19	Chen X, Sooch G, Demaree IS, White FA and Obukhov AG: Transient receptor potential canonical (TRPC) channels: Then and now. Cells. 9:19832020. View Article : Google Scholar : PubMed/NCBI
20	He B, Liu F, Ruan J, Li A, Chen J, Li R, Shen J, Zheng D and Luo R: Silencing TRPC1 expression inhibits invasion of CNE2 nasopharyngeal tumor cells. Oncol Rep. 27:1548–1554. 2012.PubMed/NCBI
21	Ong HL and Ambudkar IS: The dynamic complexity of the TRPC1 channelosome. Channels (Austin). 5:424–431. 2011. View Article : Google Scholar : PubMed/NCBI
22	Liu X, Zou J, Su J, Lu Y, Zhang J, Li L and Yin F: Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer. Int J Oncol. 48:243–252. 2016. View Article : Google Scholar
23	Yang SL, Cao Q, Zhou KC, Feng YJ and Wang YZ: Transient receptor potential channel C3 contributes to the progression of human ovarian cancer. Oncogene. 28:1320–1328. 2009. View Article : Google Scholar : PubMed/NCBI
24	Tao X, Zhao N, Jin H, Zhang Z, Liu Y, Wu J, Bast RC Jr, Yu Y and Feng Y: FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3. Endocr Relat Cancer. 20:415–429. 2013. View Article : Google Scholar : PubMed/NCBI
25	Li S, Jiang K, Li J, Hao X, Chu W, Luo C, Zhu Y, Xie R and Chen B: Estrogen enhances the proliferation and migration of ovarian cancer cells by activating transient receptor potential channel C3. J Ovarian Res. 13:202020. View Article : Google Scholar : PubMed/NCBI
26	Liu EL, Zhou YX, Li J, Zhang DH and Liang F: Long-chain non-coding RNA SNHG3 promotes the growth of ovarian cancer cells by targeting miR-339-5p/TRPC3 axis. Onco Targets Ther. 13:10959–10971. 2020. View Article : Google Scholar : PubMed/NCBI
27	Shen Z, Gu L, Liu Y, Wang L, Zhu J, Tang S, Wei X, Wang J, Zhang S, Wang X, et al: PLAA suppresses ovarian cancer metastasis via METTL3-mediated m⁶A modification of TRPC3 mRNA. Oncogene. 41:4145–4158. 2022. View Article : Google Scholar : PubMed/NCBI
28	Farfariello V, Gordienko DV, Mesilmany L, Touil Y, Germain E, Fliniaux I, Desruelles E, Gkika D, Roudbaraki M, Shapovalov G, et al: TRPC3 shapes the ER-mitochondria Ca²⁺ transfer characterizing tumour-promoting senescence. Nat Commun. 13:9562022. View Article : Google Scholar
29	Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD and Julius D: The capsaicin receptor: A heat-activated ion channel in the pain pathway. Nature. 389:816–824. 1997. View Article : Google Scholar : PubMed/NCBI
30	Gunthorpe MJ, Benham CD, Randall A and Davis JB: The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharmacol Sci. 23:183–191. 2002. View Article : Google Scholar : PubMed/NCBI
31	Wang Z, Dong J, Tian W, Qiao S and Wang H: Role of TRPV1 ion channel in cervical squamous cell carcinoma genesis. Front Mol Biosci. 9:9802622022. View Article : Google Scholar : PubMed/NCBI
32	Lucido CT, Wynja E, Madeo M, Williamson CS, Schwartz LE, Imblum BA, Drapkin R and Vermeer PD: Innervation of cervical carcinoma is mediated by cancer-derived exosomes. Gynecol Oncol. 154:228–235. 2019. View Article : Google Scholar : PubMed/NCBI
33	Han GH, Chay DB, Nam S, Cho H, Chung JY and Kim JH: Prognostic significance of transient receptor potential vanilloid type 1 (TRPV1) and phosphatase and tension homolog (PTEN) in epithelial ovarian cancer. Cancer Genomics Proteomics. 17:309–319. 2020. View Article : Google Scholar : PubMed/NCBI
34	Wang YY, Lee KT, Lim MC and Choi JH: TRPV1 antagonist DWP05195 induces ER stress-dependent apoptosis through the ROS-p38-CHOP pathway in human ovarian cancer cells. Cancers (Basel). 12:17022020. View Article : Google Scholar : PubMed/NCBI
35	Di Y, Xu T, Tian Y, Ma T, Qu D, Wang Y, Lin Y, Bao D, Yu L, Liu S and Wang A: Ursolic acid protects against cisplatin-induced ototoxicity by inhibiting oxidative stress and TRPV1-mediated Ca2+-signaling. Int J Mol Med. 46:806–816. 2020. View Article : Google Scholar : PubMed/NCBI
36	Santoni G, Amantini C, Maggi F, Marinelli O, Santoni M, Nabissi M and Morelli MB: The TRPV2 cation channels: From urothelial cancer invasiveness to glioblastoma multiforme interactome signature. Lab Invest. 100:186–198. 2020. View Article : Google Scholar
37	Liberati S, Morelli MB, Amantini C, Farfariello V, Santoni M, Conti A, Nabissi M, Cascinu S and Santoni G: Loss of TRPV2 homeostatic control of cell proliferation drives tumor progression. Cells. 3:112–128. 2014. View Article : Google Scholar : PubMed/NCBI
38	Fraguas-Sánchez AI, Fernández-Carballido A, Delie F, Cohen M, Martin-Sabroso C, Mezzanzanica D, Figini M, Satta A and Torres-Suárez AI: Enhancing ovarian cancer conventional chemotherapy through the combination with cannabidiol loaded microparticles. Eur J Pharm Biopharm. 154:246–258. 2020. View Article : Google Scholar : PubMed/NCBI
39	Griffiths C, Aikins J, Warshal D and Ostrovsky O: Can cannabidiol affect the efficacy of chemotherapy and epigenetic treatments in cancer? Biomolecules. 11:7662021. View Article : Google Scholar : PubMed/NCBI
40	Dutta B, Arya RK, Goswami R, Alharbi MO, Sharma S and Rahaman SO: Role of macrophage TRPV4 in inflammation. Lab Invest. 100:178–185. 2020. View Article : Google Scholar :
41	Wang K, Feng X, Zheng L, Chai Z, Yu J, You X, Li X and Cheng X: TRPV4 is a prognostic biomarker that correlates with the immunosuppressive microenvironment and chemoresistance of anti-cancer drugs. Front Mol Biosci. 8:6905002021. View Article : Google Scholar : PubMed/NCBI
42	Zhang C, Xu C, Ma C, Zhang Q, Bu S, Zhang DL, Yu L and Wang H: TRPs in ovarian serous cystadenocarcinoma: The expression patterns, prognostic roles, and potential therapeutic targets. Front Mol Biosci. 9:9154092022. View Article : Google Scholar : PubMed/NCBI
43	Yu S, Huang S, Ding Y, Wang W, Wang A and Lu Y: Transient receptor potential ion-channel subfamily V member 4: A potential target for cancer treatment. Cell Death Dis. 10:4972019. View Article : Google Scholar : PubMed/NCBI
44	Bödding M and Flockerzi V: Ca2+ dependence of the Ca2+-selective TRPV6 channel. J Biol Chem. 279:36546–36552. 2004. View Article : Google Scholar : PubMed/NCBI
45	Gees M, Colsoul B and Nilius B: The role of transient receptor potential cation channels in Ca2+ signaling. Cold Spring Harb Perspect Biol. 2:a0039622010. View Article : Google Scholar : PubMed/NCBI
46	Lehen'kyi V, Flourakis M, Skryma R and Prevarskaya N: TRPV6 channel controls prostate cancer cell proliferation via Ca(2+)/NFAT-dependent pathways. Oncogene. 26:7380–7385. 2007. View Article : Google Scholar : PubMed/NCBI
47	Xu X, Li N, Wang Y, Yu J and Mi J: Calcium channel TRPV6 promotes breast cancer metastasis by NFATC2IP. Cancer Lett. 519:150–160. 2021. View Article : Google Scholar : PubMed/NCBI
48	Xue H, Wang Y, MacCormack TJ, Lutes T, Rice C, Davey M, Dugourd D, Ilenchuk TT and Stewart JM: Inhibition of transient receptor potential vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model. J Cancer. 9:3196–3207. 2018. View Article : Google Scholar : PubMed/NCBI
49	Jiang Y, Gou H, Zhu J, Tian S and Yu L: Lidocaine inhibits the invasion and migration of TRPV6-expressing cancer cells by TRPV6 downregulation. Oncol Lett. 12:1164–1170. 2016. View Article : Google Scholar : PubMed/NCBI
50	Wang X, Li G, Zhang Y, Li L, Qiu L, Qian Z, Zhou S, Wang X, Li Q and Zhang H: Pan-cancer analysis reveals genomic and clinical characteristics of TRPV channel-related genes. Front Oncol. 12:8131002022. View Article : Google Scholar : PubMed/NCBI
51	Tong Q, Zhang W, Conrad K, Mostoller K, Cheung JY, Peterson BZ and Miller BA: Regulation of the transient receptor potential channel TRPM2 by the Ca2+ sensor calmodulin. J Biol Chem. 281:9076–9085. 2006. View Article : Google Scholar : PubMed/NCBI
52	Orfanelli U, Wenke AK, Doglioni C, Russo V, Bosserhoff AK and Lavorgna G: Identification of novel sense and antisense transcription at the TRPM2 locus in cancer. Cell Res. 18:1128–1140. 2008. View Article : Google Scholar : PubMed/NCBI
53	Ding Y, Tan X, Abasi A, Dai Y, Wu R, Zhang T, Li K, Yan M and Huang X: LncRNA TRPM2-AS promotes ovarian cancer progression and cisplatin resistance by sponging miR-138-5pto release SDC3 mRNA. Aging (Albany NY). 13:6832–6848. 2021. View Article : Google Scholar : PubMed/NCBI
54	Dai W, Bai Y, Hebda L, Zhong X, Liu J, Kao J and Duan C: Calcium deficiency-induced and TRP channel-regulated IGF1R-PI3K-Akt signaling regulates abnormal epithelial cell proliferation. Cell Death Differ. 21:568–581. 2014. View Article : Google Scholar :
55	Abed E, Martineau C and Moreau R: Role of melastatin transient receptor potential 7 channels in the osteoblastic differentiation of murine MC3T3 cells. Calcif Tissue Int. 88:246–253. 2011. View Article : Google Scholar : PubMed/NCBI
56	Yee NS, Kazi AA and Yee RK: Cellular and developmental biology of TRPM7 channel-kinase: Implicated roles in cancer. Cells. 3:751–777. 2014. View Article : Google Scholar : PubMed/NCBI
57	Wang J, Xiao L, Luo CH, Zhou H, Hu J, Tang YX, Fang KN and Zhang Y: Overexpression of TRPM7 is associated with poor prognosis in human ovarian carcinoma. Asian Pac J Cancer Prev. 15:3955–3958. 2014. View Article : Google Scholar : PubMed/NCBI
58	Wang J, Liao QJ, Zhang Y, Zhou H, Luo CH, Tang J, Wang Y, Tang Y, Zhao M, Zhao XH, et al: TRPM7 is required for ovarian cancer cell growth, migration and invasion. Biochem Biophys Res Commun. 454:547–553. 2014. View Article : Google Scholar : PubMed/NCBI
59	Liu L, Wu N, Wang Y, Zhang X, Xia B, Tang J, Cai J, Zhao Z, Liao Q and Wang J: TRPM7 promotes the epithelial-mesenchymal transition in ovarian cancer through the calcium-related PI3K/AKT oncogenic signaling. J Exp Clin Cancer Res. 38:1062019. View Article : Google Scholar
60	Catterall WA: Voltage-gated calcium channels. Cold Spring Harb Perspect Biol. 3:a0039472011. View Article : Google Scholar : PubMed/NCBI
61	Li W, Zhang SL, Wang N, Zhang BB and Li M: Blockade of T-type Ca(2+) channels inhibits human ovarian cancer cell proliferation. Cancer Invest. 29:339–346. 2011. View Article : Google Scholar : PubMed/NCBI
62	Jang SJ, Choi HW, Choi DL, Cho S, Rim HK, Choi HE, Kim KS, Huang M, Rhim H, Lee KT and Lee JY: In vitro cytotoxicity on human ovarian cancer cells by T-type calcium channel blockers. Bioorg Med Chem Lett. 23:6656–6662. 2013. View Article : Google Scholar : PubMed/NCBI
63	Dziegielewska B, Casarez EV, Yang WZ, Gray LS, Dziegielewski J and Slack-Davis JK: T-type Ca2+ channel inhibition sensitizes ovarian cancer to carboplatin. Mol Cancer Ther. 15:460–470. 2016. View Article : Google Scholar : PubMed/NCBI
64	Mir R, Stanzani E, Martinez-Soler F, Villanueva A, Vidal A, Condom E, Ponce J, Gil J, Tortosa A and Giménez-Bonafé P: YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression. Gynecol Oncol. 132:211–220. 2014. View Article : Google Scholar
65	Fornaro L, Vivaldi C, Lin D, Xue H, Falcone A, Wang Y, Crea F and Bootman MD: Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation. PLoS One. 12:e01828182017. View Article : Google Scholar : PubMed/NCBI
66	Mertens-Walker I, Bolitho C, Baxter RC and Marsh DJ: Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase C{delta}. Endocr Relat Cancer. 17:335–349. 2010. View Article : Google Scholar : PubMed/NCBI
67	Kim EK, Ha JM, Kim YW, Jin SY, Ha HK and Bae SS: Inhibitory role of polyunsaturated fatty acids on lysophosphatidic acid-induced cancer cell migration and adhesion. FEBS Lett. 588:2971–2977. 2014. View Article : Google Scholar : PubMed/NCBI
68	Lee H, Kim JW, Kim DK, Choi DK, Lee S, Yu JH, Kwon OB, Lee J, Lee DS, Kim JH and Min SH: Calcium channels as novel therapeutic targets for ovarian cancer stem cells. Int J Mol Sci. 21:23272020. View Article : Google Scholar : PubMed/NCBI
69	Lee H, Kwon OB, Lee JE, Jeon YH, Lee DS, Min SH and Kim JW: Repositioning trimebutine maleate as a cancer treatment targeting ovarian cancer stem cells. Cells. 10:9182021. View Article : Google Scholar : PubMed/NCBI
70	Chang X and Dong Y: CACNA1C is a prognostic predictor for patients with ovarian cancer. J Ovarian Res. 14:882021. View Article : Google Scholar : PubMed/NCBI
71	Niemeyer BA: Changing calcium: CRAC channel (STIM and Orai) expression, splicing, and posttranslational modifiers. Am J Physiol Cell Physiol. 310:C701–C709. 2016. View Article : Google Scholar : PubMed/NCBI
72	Khan HY, Mazahir I, Reddy S, Fazili F and Azmi A: Roles of CRAC channel in cancer: Implications for therapeutic development. Expert Rev Precis Med Drug Dev. 5:371–382. 2020. View Article : Google Scholar : PubMed/NCBI
73	Abdelazeem KNM, Droppova B, Sukkar B, Al-Maghout T, Pelzl L, Zacharopoulou N, Ali Hassan NH, Abdel-Fattah KI, Stournaras C and Lang F: Upregulation of Orai1 and STIM1 expression as well as store-operated Ca²⁺ entry in ovary carcinoma cells by placental growth factor. Biochem Biophys Res Commun. 512:467–472. 2019. View Article : Google Scholar : PubMed/NCBI
74	Schmidt S, Liu G, Liu G, Yang W, Honisch S, Pantelakos S, Stournaras C, Hönig A and Lang F: Enhanced Orai1 and STIM1 expression as well as store operated Ca2+ entry in therapy resistant ovary carcinoma cells. Oncotarget. 5:4799–4810. 2014. View Article : Google Scholar : PubMed/NCBI
75	Zahid M, Beseler CL, Hall JB, LeVan T, Cavalieri EL and Rogan EG: Unbalanced estrogen metabolism in ovarian cancer. Int J Cancer. 134:2414–2423. 2014. View Article : Google Scholar :
76	Lv X, Miao C, Liu M, Wang X, Wang L and Wang D: 17β-Estradiol via Orai1 activates calcium mobilization to induce cell proliferation in epithelial ovarian cancer. J Biochem Mol Toxicol. 34:e226032020. View Article : Google Scholar
77	Ouadid-Ahidouch H, Roudbaraki M, Delcourt P, Ahidouch A, Joury N and Prevarskaya N: Functional and molecular identification of intermediate-conductance Ca(2+)-activated K(+) channels in breast cancer cells: Association with cell cycle progression. Am J Physiol Cell Physiol. 287:C125–C134. 2004. View Article : Google Scholar : PubMed/NCBI
78	Kunzelmann K: Ion channels and cancer. J Membr Biol. 205:159–173. 2005. View Article : Google Scholar : PubMed/NCBI
79	Han X, Xi L, Wang H, Huang X, Ma X, Han Z, Wu P, Ma X, Lu Y, Wang G, et al: The potassium ion channel opener NS1619 inhibits proliferation and induces apoptosis in A2780 ovarian cancer cells. Biochem Biophys Res Commun. 375:205–209. 2008. View Article : Google Scholar : PubMed/NCBI
80	Berkefeld H, Sailer CA, Bildl W, Rohde V, Thumfart JO, Eble S, Klugbauer N, Reisinger E, Bischofberger J, Oliver D, et al: BKCa-Cav channel complexes mediate rapid and localized Ca2+-activated K+ signaling. Science. 314:615–620. 2006. View Article : Google Scholar : PubMed/NCBI
81	Oeggerli M, Tian Y, Ruiz C, Wijker B, Sauter G, Obermann E, Güth U, Zlobec I, Sausbier M, Kunzelmann K and Bubendorf L: Role of KCNMA1 in breast cancer. PLoS One. 7:e416642012. View Article : Google Scholar : PubMed/NCBI
82	Samuel P, Pink RC, Caley DP, Currie JM, Brooks SA and Carter DR: Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells. Tumour Biol. 37:2565–2573. 2016. View Article : Google Scholar
83	Lundstrom K: Structural genomics of GPCRs. Trends Biotechnol. 23:103–108. 2005. View Article : Google Scholar : PubMed/NCBI
84	Oldham WM and Hamm HE: Heterotrimeric G protein activation by G-protein-coupled receptors. Nat Rev Mol Cell Biol. 9:60–71. 2008. View Article : Google Scholar
85	Tu CL, Oda Y, Komuves L and Bikle DD: The role of the calcium-sensing receptor in epidermal differentiation. Cell Calcium. 35:265–273. 2004. View Article : Google Scholar : PubMed/NCBI
86	Rodland KD: The role of the calcium-sensing receptor in cancer. Cell Calcium. 35:291–295. 2004. View Article : Google Scholar : PubMed/NCBI
87	Yan S, Yuan C, Yang Q, Li X, Yang N, Liu X, Dong R, Zhang X, Yuan Z, Zhang N and Kong B: A genetic polymorphism (rs17251221) in the calcium-sensing receptor is associated with ovarian cancer susceptibility. Oncol Rep. 34:2151–2155. 2015. View Article : Google Scholar : PubMed/NCBI
88	Park KS, Kim MK, Im DS and Bae YS: Effect of lysophosphatidylglycerol on several signaling molecules in OVCAR-3 human ovarian cancer cells: Involvement of pertussis toxin-sensitive G-protein coupled receptor. Biochem Pharmacol. 73:675–681. 2007. View Article : Google Scholar
89	Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE and Prossnitz ER: GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol. 114:465–471. 2009. View Article : Google Scholar : PubMed/NCBI
90	Yan Y, Liu H, Wen H, Jiang X, Cao X, Zhang G and Liu G: The novel estrogen receptor GPER regulates the migration and invasion of ovarian cancer cells. Mol Cell Biochem. 378:1–7. 2013. View Article : Google Scholar : PubMed/NCBI
91	Heublein S, Mayr D, Friese K, Jarrin-Franco MC, Lenhard M, Mayerhofer A and Jeschke U: The G-protein-coupled estrogen receptor (GPER/GPR30) in ovarian granulosa cell tumors. Int J Mol Sci. 15:15161–15172. 2014. View Article : Google Scholar : PubMed/NCBI
92	Yan Y, Jiang X, Zhao Y, Wen H and Liu G: Role of GPER on proliferation, migration and invasion in ligand-independent manner in human ovarian cancer cell line SKOV3. Cell Biochem Funct. 33:552–559. 2015. View Article : Google Scholar : PubMed/NCBI
93	Ignatov T, Modl S, Thulig M, Weißenborn C, Treeck O, Ortmann O, Zenclussen A, Costa SD, Kalinski T and Ignatov A: GPER-1 acts as a tumor suppressor in ovarian cancer. J Ovarian Res. 6:512013. View Article : Google Scholar : PubMed/NCBI
94	Predescu DV, Crețoiu SM, Crețoiu D, Pavelescu LA, Suciu N, Radu BM and Voinea SC: G protein-coupled receptors (GPCRs)-mediated calcium signaling in ovarian cancer: Focus on GPCRs activated by neurotransmitters and inflammation-associated molecules. Int J Mol Sci. 20:55682019. View Article : Google Scholar : PubMed/NCBI
95	Xue D, Chen W and Neamati N: Discovery, structure-activity relationship study and biological evaluation of 2-thioureidothiophene-3-carboxylates as a novel class of C-X-C chemokine receptor 2 (CXCR2) antagonists. Eur J Med Chem. 204:1123872020. View Article : Google Scholar : PubMed/NCBI
96	Seo MD, Velamakanni S, Ishiyama N, Stathopulos PB, Rossi AM, Khan SA, Dale P, Li C, Ames JB, Ikura M and Taylor CW: Structural and functional conservation of key domains in InsP3 and ryanodine receptors. Nature. 483:108–112. 2012. View Article : Google Scholar : PubMed/NCBI
97	Vermassen E, Parys JB and Mauger JP: Subcellular distribution of the inositol 1,4,5-trisphosphate receptors: Functional relevance and molecular determinants. Biol Cell. 96:3–17. 2004. View Article : Google Scholar : PubMed/NCBI
98	Giannini G, Clementi E, Ceci R, Marziali G and Sorrentino V: Expression of a ryanodine receptor-Ca2+ channel that is regulated by TGF-beta. Science. 257:91–94. 1992. View Article : Google Scholar : PubMed/NCBI
99	Santulli G, Nakashima R, Yuan Q and Marks AR: Intracellular calcium release channels: An update. J Physiol. 595:3041–3051. 2017. View Article : Google Scholar : PubMed/NCBI
100	Ando H, Hirose M and Mikoshiba K: Aberrant IP₃ receptor activities revealed by comprehensive analysis of pathological mutations causing spinocerebellar ataxia 29. Proc Natl Acad Sci USA. 115:12259–12264. 2018. View Article : Google Scholar
101	Díaz-Muñoz M, de la Rosa Santander P, Juárez-Espinosa AB, Arellano RO and Morales-Tlalpan V: Granulosa cells express three inositol 1,4,5-trisphosphate receptor isoforms: Cytoplasmic and nuclear Ca2+ mobilization. Reprod Biol Endocrinol. 6:602008. View Article : Google Scholar : PubMed/NCBI
102	Hanson CJ, Bootman MD and Roderick HL: Cell signalling: IP3 receptors channel calcium into cell death. Curr Biol. 14:R933–R935. 2004. View Article : Google Scholar : PubMed/NCBI
103	Lahiri S, Roy A, Li J, Mokashi A and Baby SM: Ca2+ responses to hypoxia are mediated by IP3-R on Ca2+ store depletion. Adv Exp Med Biol. 536:25–32. 2003. View Article : Google Scholar : PubMed/NCBI
104	Lencesova L, Vlcek M, Krizanova O and Hudecova S: Hypoxic conditions increases H2S-induced ER stress in A2870 cells. Mol Cell Biochem. 414:67–76. 2016. View Article : Google Scholar : PubMed/NCBI
105	Yu Y, Xie Q, Liu W, Guo Y, Xu N, Xu L, Liu S, Li S, Xu Y and Sun L: Increased intracellular Ca²⁺ decreases cisplatin resistance by regulating iNOS expression in human ovarian cancer cells. Biomed Pharmacother. 86:8–15. 2017. View Article : Google Scholar
106	Xie Q, Xu Y, Gao W, Zhang Y, Su J, Liu Y, Guo Y, Dou M, Hu K and Sun L: TAT-fused IP3R-derived peptide enhances cisplatin sensitivity of ovarian cancer cells by increasing ER Ca2+ release. Int J Mol Med. 41:809–817. 2018.
107	Rezuchova I, Hudecova S, Soltysova A, Matuskova M, Durinikova E, Chovancova B, Zuzcak M, Cihova M, Burikova M, Penesova A, et al: Type 3 inositol 1,4,5-trisphosphate receptor has antiapoptotic and proliferative role in cancer cells. Cell Death Dis. 10:1862019. View Article : Google Scholar : PubMed/NCBI
108	Sneyers F, Rosa N and Bultynck G: Type 3 IP₃ receptors driving oncogenesis. Cell Calcium. 86:1021412020. View Article : Google Scholar
109	Xue Y, Morris JL, Yang K, Fu Z, Zhu X, Johnson F, Meehan B, Witkowski L, Yasmeen A, Golenar T, et al: SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca²⁺ flux to mitochondria. Nat Commun. 12:54042021. View Article : Google Scholar
110	Kucukkaya B, Erdag D, Akbas F and Yalcintepe L: The effect of iron on the expression levels of calcium related gene in cisplatin resistant epithelial ovarian cancer cells. Explor Target Antitumor Ther. 2:309–322. 2021.PubMed/NCBI
111	Meissner G: The structural basis of ryanodine receptor ion channel function. J Gen Physiol. 149:1065–1089. 2017. View Article : Google Scholar : PubMed/NCBI
112	Mariot P, Prevarskaya N, Roudbaraki MM, Le Bourhis X, Van Coppenolle F, Vanoverberghe K and Skryma R: Evidence of functional ryanodine receptor involved in apoptosis of prostate cancer (LNCaP) cells. Prostate. 43:205–214. 2000. View Article : Google Scholar : PubMed/NCBI
113	Zhang L, Liu Y, Song F, Zheng H, Hu L, Lu H, Liu P, Hao X, Zhang W and Chen K: Functional SNP in the microRNA-367 binding site in the 3'UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification. Proc Natl Acad Sci USA. 108:13653–13658. 2011. View Article : Google Scholar : PubMed/NCBI
114	Schmitt K, Molfenter B, Laureano NK, Tawk B, Bieg M, Hostench XP, Weichenhan D, Ullrich ND, Shang V, Richter D, et al: Somatic mutations and promotor methylation of the ryanodine receptor 2 is a common event in the pathogenesis of head and neck cancer. Int J Cancer. 145:3299–3310. 2019. View Article : Google Scholar : PubMed/NCBI
115	Andruska ND, Zheng X, Yang X, Mao C, Cherian MM, Mahapatra L, Helferich WG and Shapiro DJ: Estrogen receptor α inhibitor activates the unfolded protein response, blocks protein synthesis, and induces tumor regression. Proc Natl Acad Sci USA. 112:4737–4742. 2015. View Article : Google Scholar
116	Zheng X, Andruska N, Lambrecht MJ, He S, Parissenti A, Hergenrother PJ, Nelson ER and Shapiro DJ: Targeting multidrug-resistant ovarian cancer through estrogen receptor α dependent ATP depletion caused by hyperactivation of the unfolded protein response. Oncotarget. 9:14741–14753. 2018. View Article : Google Scholar
117	Williams CJ and Erickson GF: Morphology and Physiology of the Ovary. Endotext. Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, et al: South Dartmouth, MA: MDText.com, Inc.; 2000
118	Cui C, Merritt R, Fu L and Pan Z: Targeting calcium signaling in cancer therapy. Acta Pharm Sin B. 7:3–17. 2017. View Article : Google Scholar : PubMed/NCBI
119	Bowen NJ, Walker LD, Matyunina LV, Logani S, Totten KA, Benigno BB and McDonald JF: Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Med Genomics. 2:712009. View Article : Google Scholar : PubMed/NCBI
120	Seo JA, Kim B, Dhanasekaran DN, Tsang BK and Song YS: Curcumin induces apoptosis by inhibiting sarco/endoplasmic reticulum Ca2+ ATPase activity in ovarian cancer cells. Cancer Lett. 371:30–37. 2016. View Article : Google Scholar
121	Sun Z, Zhang H, Wang X, Wang QC, Zhang C, Wang JQ, Wang YH, An CQ, Yang KY, Wang Y, et al: TMCO1 is essential for ovarian follicle development by regulating ER Ca²⁺ store of granulosa cells. Cell Death Differ. 25:1686–1701. 2018. View Article : Google Scholar : PubMed/NCBI
122	Huang N, Yu Y and Qiao J: Dual role for the unfolded protein response in the ovary: Adaption and apoptosis. Protein Cell. 8:14–24. 2017. View Article : Google Scholar :
123	Peluso JJ: Basic fibroblast growth factor (bFGF) regulation of the plasma membrane calcium ATPase (PMCA) as part of an anti-apoptotic mechanism of action. Biochem Pharmacol. 66:1363–1369. 2003. View Article : Google Scholar : PubMed/NCBI
124	Solár P and Sytkowski AJ: Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780. Cancer Lett. 309:11–18. 2011. View Article : Google Scholar : PubMed/NCBI
125	Kucukkaya B, Basoglu H, Erdag D, Akbas F, Susgun S and Yalcintepe L: Calcium homeostasis in cisplatin resistant epithelial ovarian cancer. Gen Physiol Biophys. 38:353–363. 2019. View Article : Google Scholar : PubMed/NCBI
126	Baughman JM, Perocchi F, Girgis HS, Plovanich M, Belcher-Timme CA, Sancak Y, Bao XR, Strittmatter L, Goldberger O, Bogorad RL, et al: Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. Nature. 476:341–345. 2011. View Article : Google Scholar : PubMed/NCBI
127	Marchi S and Pinton P: The mitochondrial calcium uniporter complex: Molecular components, structure and physiopathological implications. J Physiol. 592:829–839. 2014. View Article : Google Scholar :
128	Patron M, Checchetto V, Raffaello A, Teardo E, Vecellio Reane D, Mantoan M, Granatiero V, Szabò I, De Stefani D and Rizzuto R: MICU1 and MICU2 finely tune the mitochondrial Ca2+ uniporter by exerting opposite effects on MCU activity. Mol Cell. 53:726–737. 2014. View Article : Google Scholar : PubMed/NCBI
129	Denton RM: Regulation of mitochondrial dehydrogenases by calcium ions. Biochim Biophys Acta. 1787:1309–1316. 2009. View Article : Google Scholar : PubMed/NCBI
130	Chakraborty PK, Mustafi SB, Xiong X, Dwivedi SKD, Nesin V, Saha S, Zhang M, Dhanasekaran D, Jayaraman M, Mannel R, et al: MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 8:146342017. View Article : Google Scholar : PubMed/NCBI
131	Hempel N and Trebak M: Crosstalk between calcium and reactive oxygen species signaling in cancer. Cell Calcium. 63:70–96. 2017. View Article : Google Scholar : PubMed/NCBI
132	Porporato PE, Payen VL, Pérez-Escuredo J, De Saedeleer CJ, Danhier P, Copetti T, Dhup S, Tardy M, Vazeille T, Bouzin C, et al: A mitochondrial switch promotes tumor metastasis. Cell Rep. 8:754–766. 2014. View Article : Google Scholar : PubMed/NCBI
133	Moloney JN and Cotter TG: ROS signalling in the biology of cancer. Semin Cell Dev Biol. 80:50–64. 2018. View Article : Google Scholar
134	Ham J, Lim W, Kim K, Heo YM, Ryu SM, Lee D, Kim JJ and Song G: Gentisyl alcohol inhibits proliferation and induces apoptosis via mitochondrial dysfunction and regulation of MAPK and PI3K/AKT pathways in epithelial ovarian cancer cells. Mar Drugs. 17:3312019. View Article : Google Scholar : PubMed/NCBI
135	Bae H, Park S, Ham J, Song J, Hong T, Choi JH, Song G and Lim W: ER-mitochondria calcium flux by β-sitosterol promotes cell death in ovarian cancer. Antioxidants (Basel). 10:15832021. View Article : Google Scholar
136	Bae H, Park S, Yang C, Song G and Lim W: Disruption of endoplasmic reticulum and ROS production in human ovarian cancer by campesterol. Antioxidants (Basel). 10:3792021. View Article : Google Scholar : PubMed/NCBI
137	Bae H, Song G and Lim W: Stigmasterol causes ovarian cancer cell apoptosis by inducing endoplasmic reticulum and mitochondrial dysfunction. Pharmaceutics. 12:4882020. View Article : Google Scholar : PubMed/NCBI
138	Bae H, Lee JY, Song J, Song G and Lim W: Osthole interacts with an ER-mitochondria axis and facilitates tumor suppression in ovarian cancer. J Cell Physiol. 236:1025–1042. 2021. View Article : Google Scholar
139	Bae H, Lee JY, Song G and Lim W: Fucosterol suppresses the progression of human ovarian cancer by inducing mitochondrial dysfunction and endoplasmic reticulum stress. Mar Drugs. 18:2612020. View Article : Google Scholar : PubMed/NCBI
140	Bae H, Song G, Lee JY, Hong T, Chang MJ and Lim W: Laminarin-derived from brown algae suppresses the growth of ovarian cancer cells via mitochondrial dysfunction and ER stress. Mar Drugs. 18:1522020. View Article : Google Scholar : PubMed/NCBI
141	Lim W, An Y, Yang C, Bazer FW and Song G: Chrysophanol induces cell death and inhibits invasiveness via mitochondrial calcium overload in ovarian cancer cells. J Cell Biochem. 119:10216–10227. 2018. View Article : Google Scholar : PubMed/NCBI
142	Lim W, Ryu S, Bazer FW, Kim SM and Song G: Chrysin attenuates progression of ovarian cancer cells by regulating signaling cascades and mitochondrial dysfunction. J Cell Physiol. 233:3129–3140. 2018. View Article : Google Scholar
143	Rogalska A, Szula E, Gajek A, Marczak A and Jóźwiak Z: Activation of apoptotic pathway in normal, cancer ovarian cells by epothilone B. Environ Toxicol Pharmacol. 36:600–610. 2013. View Article : Google Scholar : PubMed/NCBI
144	Giorgi C, Baldassari F, Bononi A, Bonora M, De Marchi E, Marchi S, Missiroli S, Patergnani S, Rimessi A, Suski JM, et al: Mitochondrial Ca(2+) and apoptosis. Cell Calcium. 52:36–43. 2012. View Article : Google Scholar : PubMed/NCBI
145	Honrath B, Metz I, Bendridi N, Rieusset J, Culmsee C and Dolga AM: Glucose-regulated protein 75 determines ER-mitochondrial coupling and sensitivity to oxidative stress in neuronal cells. Cell Death Discov. 3:170762017. View Article : Google Scholar
146	Ma L, Wang H, Wang C, Su J, Xie Q, Xu L, Yu Y, Liu S, Li S, Xu Y and Li Z: Failure of elevating calcium induces oxidative stress tolerance and imparts cisplatin resistance in ovarian cancer cells. Aging Dis. 7:254–266. 2016. View Article : Google Scholar : PubMed/NCBI
147	Xu L, Xie Q, Qi L, Wang C, Xu N, Liu W, Yu Y, Li S and Xu Y: Bcl-2 overexpression reduces cisplatin cytotoxicity by decreasing ER-mitochondrial Ca2+ signaling in SKOV3 cells. Oncol Rep. 39:985–992. 2018.
148	Xie Q, Su J, Jiao B, Shen L, Ma L, Qu X, Yu C, Jiang X, Xu Y and Sun L: ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca2+ signal transduction in human ovarian cancer cells. Int J Oncol. 49:2507–2519. 2016. View Article : Google Scholar : PubMed/NCBI
149	Li J, Qi F, Su H, Zhang C, Zhang Q, Chen Y, Chen P, Su L, Chen Y, Yang Y, et al: GRP75-faciliated mitochondria-associated ER membrane (MAM) integrity controls cisplatin-resistance in ovarian cancer patients. Int J Biol Sci. 18:2914–2931. 2022. View Article : Google Scholar : PubMed/NCBI
150	Li L, Zeng S, Guo L, Huang P, Xi J, Feng J, Li Q, Li Y, Xiao X, Yan R and Zhang J: Long noncoding RNA RMRP contributes to paclitaxel sensitivity of ovarian cancer by regulating miR-580-3p/MICU1 signaling. J Oncol. 2022:83019412022.PubMed/NCBI
151	Bresnick AR, Weber DJ and Zimmer DB: S100 proteins in cancer. Nat Rev Cancer. 15:96–109. 2015. View Article : Google Scholar : PubMed/NCBI
152	Zimmer DB, Eubanks JO, Ramakrishnan D and Criscitiello MF: Evolution of the S100 family of calcium sensor proteins. Cell Calcium. 53:170–179. 2013. View Article : Google Scholar
153	Bai Y, Li LD, Li J and Lu X: Prognostic values of S100 family members in ovarian cancer patients. BMC Cancer. 18:12562018. View Article : Google Scholar : PubMed/NCBI
154	Hua X, Zhang H, Jia J, Chen S, Sun Y and Zhu X: Roles of S100 family members in drug resistance in tumors: Status and prospects. Biomed Pharmacother. 127:1101562020. View Article : Google Scholar : PubMed/NCBI
155	Tian T, Li X, Hua Z, Ma J, Liu Z, Chen H and Cui Z: S100A1 promotes cell proliferation and migration and is associated with lymph node metastasis in ovarian cancer. Discov Med. 23:235–245. 2017.PubMed/NCBI
156	Buckley NE, D'Costa Z, Kaminska M and Mullan PB: S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability. Cell Death Dis. 5:e10702014. View Article : Google Scholar : PubMed/NCBI
157	Kikuchi N, Horiuchi A, Osada R, Imai T, Wang C, Chen X and Konishi I: Nuclear expression of S100A4 is associated with aggressive behavior of epithelial ovarian carcinoma: An important autocrine/paracrine factor in tumor progression. Cancer Sci. 97:1061–1069. 2006. View Article : Google Scholar : PubMed/NCBI
158	Horiuchi A, Hayashi T, Kikuchi N, Hayashi A, Fuseya C, Shiozawa T and Konishi I: Hypoxia upregulates ovarian cancer invasiveness via the binding of HIF-1α to a hypoxia-induced, methylation-free hypoxia response element of S100A4 gene. Int J Cancer. 131:1755–1767. 2012. View Article : Google Scholar : PubMed/NCBI
159	Yan W, Chen J, Chen Z and Chen H: Deregulated miR-296/S100A4 axis promotes tumor invasion by inducing epithelial-mesenchymal transition in human ovarian cancer. Am J Cancer Res. 6:260–269. 2016.PubMed/NCBI
160	Link T, Kuhlmann JD, Kobelt D, Herrmann P, Vassileva YD, Kramer M, Frank K, Göckenjan M, Wimberger P and Stein U: Clinical relevance of circulating MACC1 and S100A4 transcripts for ovarian cancer. Mol Oncol. 13:1268–1279. 2019. View Article : Google Scholar : PubMed/NCBI
161	Deo AN, Thorat R, Dhadve AC, De A, Rekhi B and Ray P: IGF1R-α6 integrin-S100A4 network governs the organ-specific metastasis of chemoresistant epithelial ovarian cancer cells. Biochim Biophys Acta Mol Basis Dis. 1868:1662822022. View Article : Google Scholar
162	Schäfer BW, Fritschy JM, Murmann P, Troxler H, Durussel I, Heizmann CW and Cox JA: Brain S100A5 is a novel calcium-, zinc-, and copper ion-binding protein of the EF-hand superfamily. J Biol Chem. 275:30623–30630. 2000. View Article : Google Scholar : PubMed/NCBI
163	Wei BR, Hoover SB, Ross MM, Zhou W, Meani F, Edwards JB, Spehalski EI, Risinger JI, Alvord WG, Quiñones OA, et al: Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients. PLoS One. 4:e76702009. View Article : Google Scholar : PubMed/NCBI
164	Lin M, Xia B, Qin L, Chen H and Lou G: S100A7 regulates ovarian cancer cell metastasis and chemoresistance through MAPK signaling and is targeted by miR-330-5p. DNA Cell Biol. 37:491–500. 2018. View Article : Google Scholar : PubMed/NCBI
165	Nymoen DA, Hetland Falkenthal TE, Holth A, Ow GS, Ivshina AV, Tropé CG, Kuznetsov VA, Staff AC and Davidson B: Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma. Gynecol Oncol. 139:30–39. 2015. View Article : Google Scholar : PubMed/NCBI
166	Lokman NA, Pyragius CE, Ruszkiewicz A, Oehler MK and Ricciardelli C: Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome. Transl Res. 171:83–95.e1-e2. 2016. View Article : Google Scholar : PubMed/NCBI
167	Wang L, Yan W, Li X, Liu Z, Tian T, Chen T, Zou L and Cui Z: S100A10 silencing suppresses proliferation, migration and invasion of ovarian cancer cells and enhances sensitivity to carboplatin. J Ovarian Res. 12:1132019. View Article : Google Scholar : PubMed/NCBI
168	Xuan L, Sun Z, Wang J and Gao S: lncRNA SNHG8 promotes ovarian cancer progression through serving as sponge for miR-1270 to regulate S100A11 expression. J Gene Med. e33152021.
169	Li W, Cui Z, Kong Y, Liu X and Wang X: Serum levels of S100A11 and MMP-9 in patients with epithelial ovarian cancer and their clinical significance. Biomed Res Int. 2021:73412472021.PubMed/NCBI
170	Qian J, Ding F, Luo A, Liu Z and Cui Z: Overexpression of S100A14 in human serous ovarian carcinoma. Oncol Lett. 11:1113–1119. 2016. View Article : Google Scholar : PubMed/NCBI
171	Sturchler E, Cox JA, Durussel I, Weibel M and Heizmann CW: S100A16, a novel calcium-binding protein of the EF-hand superfamily. J Biol Chem. 281:38905–38917. 2006. View Article : Google Scholar : PubMed/NCBI
172	Yang T, Cheng J, Yang Y, Qi W, Zhao Y, Long H, Xie R and Zhu B: S100B mediates stemness of ovarian cancer stem-like cells through inhibiting p53. Stem Cells. 35:325–336. 2017. View Article : Google Scholar
173	Yang T, Cheng J, You J, Yan B, Liu H and Li F: S100B promotes chemoresistance in ovarian cancer stem cells by regulating p53. Oncol Rep. 40:1574–1582. 2018.PubMed/NCBI
174	Wang X, Tian T, Li X, Zhao M, Lou Y, Qian J, Liu Z, Chen H and Cui Z: High expression of S100P is associated with unfavorable prognosis and tumor progression in patients with epithelial ovarian cancer. Am J Cancer Res. 5:2409–2421. 2015.PubMed/NCBI
175	Wang Q, He Z, Gao J, Hu S, Huang M, Liu M, Zheng J and Tang H: S100P sensitizes ovarian cancer cells to carboplatin and paclitaxel in vitro. Cancer Lett. 272:277–284. 2008. View Article : Google Scholar : PubMed/NCBI
176	Ma N, Zhu L, Yang L, Cui Y and Zhan Y: Prognostic values of S100 family mRNA expression in ovarian cancer. Cancer Biomark. 25:67–78. 2019. View Article : Google Scholar : PubMed/NCBI
177	Wu B, Yu C, Zhou B, Huang T, Gao L, Liu T and Yang X: Overexpression of TROP2 promotes proliferation and invasion of ovarian cancer cells. Exp Ther Med. 14:1947–1952. 2017. View Article : Google Scholar : PubMed/NCBI
178	Dai S, Venturini E, Yadav S, Lin X, Clapp D, Steckiewicz M, Gocher-Demske AM, Hardie DG and Edelman AM: Calcium/calmodulin-dependent protein kinase kinase 2 mediates pleiotropic effects of epidermal growth factor in cancer cells. Biochim Biophys Acta Mol Cell Res. 1869:1192522022. View Article : Google Scholar : PubMed/NCBI
179	Chen LL, Xia LY, Zhang JP, Wang Y, Chen JY, Guo C and Xu WH: Saikosaponin D alleviates cancer cachexia by directly inhibiting STAT3. Phytother Res. 37:809–819. 2023. View Article : Google Scholar
180	Laski J, Singha B, Wang X, Valdés YR, Collins O and Shepherd TG: Activated CAMKKβ-AMPK signaling promotes autophagy in a spheroid model of ovarian tumour metastasis. J Ovarian Res. 13:582020. View Article : Google Scholar
181	Chen Z, Sun X, Xia Z, Wang J, Guo N and Zhang Y: CaMKK2 promotes the progression of ovarian carcinoma through the PI3K/PDK1/Akt axis. Comput Math Methods Med. 2022:71879402022.PubMed/NCBI
182	Tsuyoshi H, Wong VKW, Han Y, Orisaka M, Yoshida Y and Tsang BK: Saikosaponin-d, a calcium mobilizing agent, sensitizes chemoresistant ovarian cancer cells to cisplatin-induced apoptosis by facilitating mitochondrial fission and G2/M arrest. Oncotarget. 8:99825–99840. 2017. View Article : Google Scholar : PubMed/NCBI